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Abstract
Human chymase catalyzes the hydrolysis of peptide bonds. Three chymase inhibitors with very similar chemical structures
but highly different inhibitory profiles towards the hydrolase function of chymase were selected with the aim of elucidating
the origin of disparities in their biological activities. As a substrate (angiotensin-I) bound crystal structure is not available,
molecular docking was performed to dock the substrate into the active site. Molecular dynamics simulations of chymase
complexes with inhibitors and substrate were performed to calculate the binding orientation of inhibitors and substrate as
well as to characterize conformational changes in the active site. The results elucidate details of the 3D chymase structure as
well as the importance of K40 in hydrolase function. Binding mode analysis showed that substitution of a heavier Cl atom at
the phenyl ring of most active inhibitor produced a great deal of variation in its orientation causing the phosphinate group
to interact strongly with residue K40. Dynamics simulations revealed the conformational variation in region of V36-F41upon
substrate and inhibitor binding induced a shift in the location of K40 thus changing its interactions with them. Chymase
complexes with the most activecompound and substrate were used for development of a hybrid pharmacophore model
which was applied in databases screening. Finally, hits which bound well at the active site, exhibited key interactions and
favorable electronic properties were identified as possible inhibitors for chymase. This study not only elucidates inhibitory
mechanism of chymase inhibitors but also provides key structural insights which will aid in the rational design of novel
potent inhibitors of the enzyme. In general, the strategy applied in the current study could be a promising computational
approach and may be generally applicable to drug design for other enzymes.
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Introduction
Chymase (EC 3.4.21.39) is an enzyme of the hydrolase class that
catalyzes the hydrolysis of peptide bonds and it is abundant in
secretory granules of mast cells. Chymase is the major extravas-
cular source of vasoactive angiotensin II(Ang II), which is
generated very efficiently by human chymase via hydrolysis of
the Phe-8–His-9 bond of angiotensin I(Ang I) [1]. Chymase is
stored in mast cells in an inactive form and is released as an active
enzyme when mast cells are stimulated by injury or inflammation.
Chymase shows enzymatic activity immediately after its release
into the interstitial tissues at pH 7.4 following various stimuli in
tissues. As chymase has no enzymatic activity in normal tissues,
chymase inhibitors have the potential to be safe/non-toxic because
specific chymase inhibitors may not have effects on any other
targets in normal tissues [2]. Cardiovascular diseases are the
leading cause of death in the developed world and are now on
course to emerge as the major cause of death in the developing
world [3]. One particular manifestation of cardiovascular diseases,
heart failure (HF), is dramatically increasing in frequency. A link
between heart failure and chymase has been ascribed, and there is
an interest to develop a specific chymase inhibitor as a new
therapeutic treatment for the disease [4]. The density of cardiac
mast cells is remarkably increased in patients with heart failure,
and cardiac chymase may play an important role in the
development of several cardiovascular diseases [5]. Recently, it
was observed that chymase activation was increased in ischemic
myocardium following acute myocardial ischemia/reperfusion
(AMI-R) compared to non-ischemic and sham myocardial tissue
[6]. Chymase is also known to activate matrix metalloproteinase
(MMP)-9 by cleaving a specific site of the catalytic domain of
MMP-9. MMP-9, known as 92 kDa gelatinase, is correlated with
an increase in infarct sizeand left ventricle (LV) fibrosis following
experimental AMI [7]. Chymase also converts the precursor of
transforming growth factor-b (TGF-b)to its active form thus
contributing to vascular response to injury (Figure 1). Both TGF-b
and MMP-9 are involved in tissue inflammation and fibrosis,
resulting in organ damage [8]. Previous studies have shown the
involvement of chymase in the escalation of dermatitis and chronic
inflammation following cardiac and pulmonary fibrosis [9].
Therefore, inhibition of chymase is likely to reveal therapeutic
methods for the treatment of cardiovascular diseases, allergic
inflammation, and fibrotic disorders. Chymase inhibition may also
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be useful for preventing the progression of type 2 diabetes, along
with the prevention of diabetic retinopathy [10]. Moreover, the
role of chymase in inflammation has demonstrated its restorative
value in diseases such as chronic obstructive pulmonary disease
(COPD) and asthma [11].
Over the past 15–20 years, several peptide and non-peptide
inhibitors of chymase have been synthesized [12,13,14,15]. In
general, chymase inhibitors readily decompose in plasma, thus the
stability of the chymase inhibitors in human plasma has always
been a matter of great concern. So, there is a continuing need to
search for more stable inhibitors with high activity against human
chymase. To date, six crystal structures have been determined for
human chymase while four 3D crystal structures of chymase
enzyme bound with diverse inhibitors have been determined
andare available in the protein data bank (PDB). However, the
substrate (Ang I) bound crystal structure has not been solved yet
which has obstructed efforts to gain a deeper insight of the
structural state of the enzyme’sactive site cleft when accommo-
dating a long peptide substrate.
Chymase Structure Details
Human chymase is folded into two six-stranded b-barrels, which
are connected by three trans-domain segments (Figure 2). Human
chymase contains 13 arginine and 15 lysine residues, but only
eight glutamate and eight aspartate residues, resulting in a rather
high overall basicity. The inhibitor binding region in human
chymase is defined by residues K40, H57, Y94, N95, T96, L99,
D102, A190, F191, K192, G193, S195, V213, S214, Y215, G216,
and R217. This is mostly polar region because of main chain
carbonyls that are arranged along the surface of the region. The
catalytic residues Ser195, Asp102, and His57 are located at the
junction of the two b-barrels, while the active-site cleft runs
perpendicular to this junction.
Some evidence exists that the residue at the position 40 has an
important role in the enzyme catalysis. Human chymase has been
identified as an efficient angiotensin converting enzyme, selectively
hydrolyzing Ang I at F8 to generate bioactive Ang II [16]. While,
Rat chymase (RMCP-I) degrades the Tyr4-Ile5 bond of Ang-I to
inactive fragments. In order to clarify this different catalysis for
Ang-I at the atomic level, Yamamoto et al. performed a study
which clearly showed the significant difference in the electrostatic
potential of the solvent surface [17]. From the modeling study of
complex structures with Ang-I, the functional difference between
both enzymes was clearly related to the electrostatic difference,
especially at the C-terminal substrate-binding site. Site-specific
mutagenesis studies have shown that K40 in human chymase
influences substrate recognition resulting in cleavage at F8 in Ang
I [18]. When K40 was mutated to A, the human enzyme became
much less specific for hydrolysis at F8 of Ang whereas Y4
hydrolysis rates(destroys bioactivity of Ang II) were enhanced 16-
fold compared to the wild-type human enzyme. Thus, K40 plays a
key role in the substrate recognition and hydrolysis based on these
studies. A previous study has revealed the substantial variation in
terms of human chymase inhibitory activity of very similar
chemical compounds [19]. In this study, a strategy that integrates
the advantages of molecular dynamics simulations, pharmaco-
phore modeling and molecular docking approaches has been
applied, in order to understand the important chemical features
that inhibit the chymase enzyme and to determine the molecular
mechanism by which these compounds act. Molecular docking is
applied to prepare the enzyme-substrate and enzyme-inhibitor
complexes when their crystal structures are not available. A hybrid
pharmacophore model was also developed using MD refined
enzyme-substrate and enzyme-inhibitor complexes. Interesting
and valuable information has been obtained from the analysis of
binding modes of inhibitors, structural changes at the active site,
and interaction energy computations which effectively explained
the differences in the activity of inhibitors. In summary, the
findings from this research could be helpful to design and identify
potentially useful novel chymase inhibitors for the treatment of
cardiovascular diseases, allergic inflammation, and fibrotic disor-
ders.
Materials and Methods
Selection of Inhibitors and Preparation of Complex
Structures
Three chemical compounds with their experimentally known
chymase inhibitory activity (IC50) data were obtained from the
literature. These compounds, labeled as C1, C2, and C3 havevery
similar chemical structures but they exhibit considerable differ-
ences in terms of chymase inhibitory activity (Figure 3) [19]. With
the aim of examining the structural changes to address the
observed differences in their inhibitory activity, chymase inhibitor
complexes were prepared for MD simulations. The crystal
structure of chymase complexed with C2 (PDB code 3N7O) was
already available in PDB and it was directly used in MD
simulations [20]. However, crystal structures of C1and C2 are not
available. Therefore, the crystal structure of chymase bound with
inhibitor C2, which has very similar structural profile with C1 and
C3 was utilized in preparing their complexes. In order to prepare a
complex structure of the most active compound C1, the similar
compound present in 3N7O was modified by replacing one of the
fluorine atoms attached to the phenyl group with chlorine while
the other fluorine atom was removed. The carbon-carbon double
bond of C2 was modified to a single bond to prepare the complex
structure of the least active compound C3. Ang I is the natural
substrate of chymase but the substrate (Ang I) bound crystal
structure has not been solved yet. Crystal structures of chymase-
MMP-9 and chymase TGF-beta complexes are also not available.
Due to the large amount computational calculations required for
each complex, extending the current study to include these two
chymase complexes is not possible. Separate studies will be
performed for chymase-MMP-9 and chymase TGF-beta com-
plexes in near future. In order to prepare complex structure of
chymase-Ang I, the chemical structure of Ang I was downloaded
from PDB(PDB code 1N9U) and docked into the active site of the
average structure prepared from a 5 ns MD simulation of chymase
apoform. In this study, the molecular docking methodology using
HADDOCK(High Ambiguity Driven protein2protein Docking)
was utilized to obtain the reliable binding mode of Ang I [21].
Molecular Dynamics Simulations
Biological systems are dynamic in nature; analyzing their
motion at the molecular and atomic level is therefore essential to
Figure 1. Chymase-dependent conversion of angiotensin I to
angiotensin II and precursors of TGF-b and MMP-9 to their
active forms.
doi:10.1371/journal.pone.0062740.g001
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understand their profound dynamic mechanisms such as switching
between active and inactive states, intercalation of drugs into
DNA, and assembly of microtubules, by studying their internal
motions [22,23,24]. Therefore, to really understand the interac-
tion mechanism of a receptor with its ligand, investigations should
be made not only to their static structures but also of the dynamic
process obtained by simulating their internal motions. Molecular
dynamics simulation stands alone as the fundamental computa-
tional tool for capturing dynamic events of scientific interest and
pharmaceutical relevance. To perform calculations, the initial
coordinates for the protein atoms were taken from the complex
structures of chymase-inhibitor, chymase-substrate complex, and
apoform. The protonation states of all ionizable residues were set
to their normal states at pH 7. Five MD simulations were
performed for systems including the apoform, inhibitors and
substrate complexes. All MD simulations were performed with
GROMOS96 forcefield using GROMACS 4.5.3 package running
on a high performance linux cluster computer [25,26]. During
MD simulations, all the protein atoms were surrounded by acubic
water box of SPC3 water molecules that extended 10 Å from the
protein and periodic boundary conditions were applied. The
systems were neutralized with Cl2 counter ions replacing the
water molecules and energy minimization was performed using
steepest descentalgorithm for 10,000 steps. A 100 ps position
restrained MD simulation was performed for every system
followed by a 5 ns production MD simulation with a time step
of 2 fs at constant pressure (1 atm) and temperature (300 K). The
electrostatic interactions were calculated by the PME algorithm
and all bonds were constrained using LINCS algorithm. A twin
range cutoff was used for long-range interactions including 9 Å for
van der Waals and 14 Å for electrostatic interactions. The
snapshots were collected at every 1 ps and stored for further
analyses of MD simulations. The system stability and behavior of
the catalytic structural components present in every system were
analyzed using the tools available with GROMACS 4.5.3 and
PyMol programs.
Development of Hybrid Pharmacophore Model
The hybrid 3D pharmacophore hypotheses were developed
using representative structures collected from the MD simulations
of C1 and Ang I complexes, and based on features identified from
C1 (the most active compound) and Ang I the substrate. The
Receptor-Ligand Pharmacophore Generation protocol of Accelrys Discov-
ery Studio v3.0 (DS), Accelrys, San Diego, USA, was applied to
accomplish this task with default parameters. This protocol
generates selective pharmacophore models based on receptor-
ligand interactions. An investigation based on the importance of all
generated pharmacophoric features was performed to select the
features to complement the very important interaction points at
the active site. Finally, the Merge pharmacophore tool of DS was used
to merge key features for the formation of a hybrid pharmaco-
Figure 2. Overall 3D structure of human chymase and the zoomed view which clearly shows the important catalytic residues.
doi:10.1371/journal.pone.0062740.g002
Figure 3. The 2D chemical structures of human chymase
inhibitors used in this study along with their IC50values.
doi:10.1371/journal.pone.0062740.g003
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phore model. Utilization of this hybrid pharmacophore model
development methodology is wholly new and different methodol-
ogy from the common feature and structure-activity relationship
based pharmacophore models employed in our previous study for
designing human chymase inhibitors [27].
Druglike Database Screening and Molecular Docking
Maybridge, and Chembrige, commercial chemical databases
containing 59 652, and 50 000 compounds, respectively, were
employed for a virtual screening procedure. However, these
databases contain a number of nondruglike compounds. As, it is
worthless to screen all the compounds of these databases and then
eliminate them in the later phase for their nondruglike properties,
the compounds not exhibiting druglike properties were excluded
from the databases prior to hybrid pharmacophore-based virtual
screening. In order to accomplish this task, compounds in these
databases were subjected to various filters for druglike structure,
such as Lipinski’s rule of five and ADMET(absorption, distribu-
tion, metabolism, excretion, and toxicity) properties [28]. Prepare
Ligands and ADMET Descriptors protocols as available in the DS
program were used in this step. After preparation of druglike
databases, the hybrid pharmacophore model was employed for
screening of these druglike databases to select the compounds
containing the hybrid pharmacophoric features identified from
both the inhibitor and the substrate. The druglike hit compounds
that were identified to have hybrid pharmacophoric features were
subjected to molecular docking studies using GOLD (Genetic
Optimization for Ligand Docking). The Prepare Ligands protocol as
implemented in DS was employed to change the ionization states
as well as to generate different tautomers and isomers of the hit
compounds. GOLD 5.1 program from Cambridge Crystallo-
graphic Data Center, UK. uses a genetic algorithm for docking
ligands into protein binding sites to explore the full range of ligand
conformational flexibility with partial flexibility of protein [29,30].
Protein coordinates from the representative structure of the
chymase-C1 complex obtained from MD simulation were used
to define the active site. The active site was defined with a 10 Å
radius around the bound inhibitor. Ten docking runs were
performed per structure unless five of the ten poses were within an
RMS deviation value of 1.5 Å. The GOLD fitness score is
calculated from the contributions of hydrogen bond and van der
Waals interactions between the protein and ligand, intramolecular
hydrogen bonds and the internal strain of the ligand. Protein-
ligand interactions were analyzed using DS. For further validation,
electronic parameters and binding free energies were calculated
for all the known active compounds and database hits using
Gaussian 09and AutoDock 4.2 programs, respectively [31,32]. The
final hit compounds with the best electronic parameters and
binding energies were selected.
Results and Discussion
Selection of Chymase Inhibitors
Three chymase inhibitors used in this study are very similar in
terms of their chemical structures but their human chymase
inhibitory activity (IC50 values) values tested using the same
biological assay were extremely different from one another
(Figure 3). The most active C1 holds the same basic scaffold as
other compounds in the study but the observed IC50 value is 17
fold higher for C1 compared to C2. It contains a chlorine atom
attached to the aromatic ring instead of two fluorine atoms for
compounds C2 and C3. Furthermore, the only difference between
the structures of C2 and C3 is the presence of a double bond
between carbon atoms in compound C2. However, in spite of
these small differences, the IC50 value of C2 is 58 nM,180 fold
more potent than its counterpart C3 (10 400 nM). Alternatively,
absence of a double bond in C3 has lowered 180 fold its IC50
value. This drastic change in the human chymase inhibitory
profiles of these very similar chemical compounds has triggered
our interest and motivated us to study the structural reasons which
may possibly explain this behavior. The recognition of structural
responses to these structurally very similar inhibitors with different
inhibitory activities can be employed in designing highly potent
novel drug candidate for further experimental investigation. It
may also aid to develop new and effective drug for the treatment of
cardiovascular diseases, allergic inflammation, and fibrotic disor-
ders.
Overall Stability of the Systems
MD simulation results of all the systems were used for
examining the stability of every system. The root mean
squaredeviation (RMSD) from initial conformation is a central
criterion used to evaluate the difference of the protein system. The
stabilityof each simulation system was evaluated based on its
RMSD (Figure 4). RMSD of the chymase-apoform displayed the
highest value compared to all other systems. While, the RMSD of
the complex with C2 inhibitor showed the lowest value among
other inhibitors. Though differences were observed in RMSD
values among the systems, they all converged to around 2.0 Å
except apoform and the Ang I-complex which had a mean value
slightly over 2.0 Å. The higher RMSD value of the Ang I-complex
(2.01 Å) depicts the structural flexibility of the system upon binding
of Ang I when compared to others. Comparison of the mean
RMSD values of C1and C2, which are 1.66 Å and 1.55 Å,
respectively, shows that the flexibility observed in the structure is
caused by the replacement of fluorine with chlorine atom in the
structure. The calculated mean RMSD values of C2 and C3 were
1.55 Å and 1.82 Å, respectively, which showed the influence of
conversion of double bond to single bond in C3. Interestingly, all
complexes have shown the RMSD values smaller than that of
apoform explaining the difference in terms of instability in
chymase complexes. The root mean square fluctuation (RMSF)
values of the systems were also calculated and plotted to compare
the flexibility of each amino acid residues of the complex. This
RMSF plot reveals the flexible regions of the systems during the
simulation time (Figure 5A). Moreover, in order to investigate the
motions about the important residues interacted with the inhibitor
in the binding site; the root mean square fluctuations (RMSF) for
all important catalytic residues were calculated and depicted in
Figure 5B. This focused RMSF plot clearly shows that none of the
important catalytic residues present in the active site has an RMSF
value more than 2Å (Figure 5B). This result has confirmed that the
catalytic machinery present in the active site was minimally
distorted upon binding of substrate and any of the inhibitors. The
amino acids, namely, K40, K192, and R217 have shown the
flexibility upon the binding of different ligands. Most of these
residues were highly mobile in the apoform of the enzyme whereas
they were stable in complex systems indicating the binding nature
of the ligands (Figure 5B). In case of C3, and chymase-Ang I
complexes, the majority of the active site residues exhibited more
fluctuation as compared to other systems. Particularly, R217
fluctuated more compared to other amino acids in the active site
indicating its flexible nature in apoform and complex systems.
Mode of Substrate Binding in Human Chymase
The representative structure of the apoform of the enzyme
selected from the MD simulation was employed to dock the
substrate Ang I into the active site cleft of chymase enzyme. In
Inhibition Mechanism of Human Chymase
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view of the fact that the crystal structure of the enzyme-substrate
complex has not been determined yet, the proposed binding mode
of the substrate is very important to understand the hydrolase
mechanism of the enzyme. Some previous studies have also
proposed its binding mode at the active site of the enzyme. In
chymase, as in other trypsin-family serine peptidases, key substrate
binding interactions occur in an active site cleft formed between
two, six-stranded b-barrel domains [33]. The nomenclature of
Schechter and Berger (1967) is adopted to designate the substrate
residues as P2, P1, P19, etc., for substrate binding mode analysis,
where P1 is the amino acid after which the peptide bond is
cleaved. In the case of chymase-mediated hydrolysis of Ang I,
interactions involving P1, P19, and P29 are particularly important.
All the ligands under study bind the same active site pocket but
they vary in terms of their molecular interactions (Figure 6). The
proposed binding mode of Ang I is that P19-H9 is positioned in
such a way to cause close hydrogen bond contacts(2.489, 2.623 Å)
with the positively charged side chain of K40 residue from a
complementary binding site S19 thus enabling the catalysis
(Figure 7A). Moreover, a p…cationic interaction was also observed
between P19 and K40. In addition, a hydrogen-bonding network
(1.633, 3.036, 3.131, and 3.280 Å) between the P29-L10 side chain
and K40 is also established which we suggest stabilizes the Ang I
extended into the protein from this point. P19-H9 of Ang I threads
through the active site S19 pocket and form a hydrogen bond with
H57 of chymase. F41 of chymase is proximal to the P29 side chain
thus providing the potential for a hydrogen bond to be formed
with the carboxylate group of P29-L10. The P4-I5 of AngI is also
able to make hydrogen bonds with the polar S218 residue of the
enzyme. The other residues of the binding site cleft such as T96,
and F191 have also formed hydrogen bonds with the substrate
(Figure 7A). The binding mode of Ang I at the active site has
formed a number of hydrogen bonds with the active site residues
throughout the simulation time indicating its strong binding
affinity (Figure 8A). The structural analysis of the active site upon
binding of substrate indicated that the catalytic residues in
substrate complex were very stable compared to the active site
of apoform except for small side chain movements that lead the
key residues like K40, H57, D102, F191, Y215, and S218 close to
the substrate for stronger molecular interactions (Figure 7B).
Significant structural changes were observed in and around the
active site thus impacting the binding mode of critical residues to
the substrate. Particularly, the change in the loop region formed by
V36-F41 has caused a critical conformational variation upon the
important K40 residue. Thus, K40 is ideally positioned to form
putative interactions with the key residues P19-H9 and P29-L10 of
substrate. Moreover, change in the conformation of the G216-
A220 loop region instigated a significant modification in position
of the S218 residue of the binding site cleft. These binding
characteristics observed from the Ang I-substrate simulation are
compared with the binding modesof inhibitors.
Binding mode Analysis of Chymase-inhibitor Complexes
Chymase-C1 complex. C1 is the most active chymase
inhibitor among the compounds under study which possess a
chlorine atom attached to the aromatic ring instead of two fluorine
atoms as in case of C2 and C3 compounds. The binding mode of
C1 at the active site has formed maximum number of hydrogen
bonds with the active site residues throughout the simulation time
indicating its excellent binding affinity as compared to C2 and C3
inhibitors (Figure 8B). The phosphinate group of C1 drove the
inhibitor to form closer interactions with the key residues K40
(2.418, 2.904 Å) and G193 (1.806 Å) of active site region
(Figure 9B). The oxygen atom of amide carbonyl group is also
involved in the formation of hydrogen bonds contacts with
K40(3.021, 3.214Å). Compound C1 also interacted with the polar
residue H57 (3.025 Å) through amide moiety. In terms of active
site flexibility upon binding of C1, the positions of key residues are
changed as compared to apoform of enzyme. The polar residue
S195 of catalytic triad has moved away to accommodate C1 at the
Figure 4. The RMSD plot to investigate the stability of the systems.
doi:10.1371/journal.pone.0062740.g004
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active site cleft. While, the charged residues K40 and R217 along
with H57 have moved closer to the inhibitor to form stronger
interactions with it, thus stabilizing the binding conformationof
C1at the active site region. The most important change in the
active site pocket upon binding of C1 is the variation in position of
K40. The loop region consisting of V36-F41 residues has moved
into the active site cleft thus changing the orientation of positively
charged K40 residue closer to the bound inhibitor. The same loop
region also fluctuated for substrate binding mode but it showed less
variation as compared to the loop fluctuation during C1 binding to
the active site of enzyme.
Chymase-C2 complex. The binding mode of C2, the mid-
active compound, also formed interactions with the key residues
inside the active site of the enzyme (Figure 9C). As compared to
C1, the placement of lighter halide F atoms instead of heavier Cl
atom at the phenyl ring in C2 has caused significant variation in its
orientation through the displacement of 3,4-difluorophenyl group
much away from the benzothiophene moiety. The phosphinate
group of C2 compound is also involved in hydrogen bond
interactions with K40 and G193 like C1 compound. Both oxygen
atoms of the phosphinate have formed hydrogen bond contacts
with the positively charged K40 (3.144, 3.212, and 2.012 Å) and
G193 (1.992 Å). Moreover, amide group has formed a hydrogen
bond interaction with H57 (2.746Å). Although, the C2 inhibitor
has exhibited interactions with the key residues, these interactions
are relatively long-ranged and less in number as compared to C1.
As far as structural flexibility of active site residues is concerned,
much variation was observed upon binding of C2 in the active site
region. Although, the same loop region consisting of V36-F41
residues has also moved into the active site region as it did upon
Figure 5. The RMSF plots of all systems (A) full protein and (B) important active site residues.
doi:10.1371/journal.pone.0062740.g005
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binding of substrate and C1 inhibitor. However, the fluctuation of
this loop was much less as compared to the chymase complex
structures of substrate and C1 inhibitor. The binding mode of C2
at the active site has also formed anumber of hydrogen bonds with
the active site residues throughout the simulation time showing its
strong binding affinity (Figure 8B).
Chymase-C3 complex. C3 is the least active chymase
inhibitor among the compounds under study and it is the
saturated analogue of C2. The conversion of one double bond
between two carbon atoms of C2 inhibitor into single bond in C3
has brought drastic change in its potency thus making it 180-fold
less potent as compared to C2. Analysis of C3 binding mode
revealed that this slight change in its structure had a great impact
on its binding conformation in the active site pocket of enzyme
(Figure 9D). The presence of single bond adjacent to amide group
made the 3,4-difluorophenyl group more able to move thus
allowing it closer to the 30 s loop. This flexible movement of the
3,4-difluorophenyl group leads to the benzothiophene moiety
becoming tilted further away from the catalytically very important
K40 residue of active site. Thus, the phosphinate group of C3 was
unable to generate any kind of interactions with K40. C3 did not
exhibit any interactions with key residues like H57, G193. The F
atom of 3,4-difluorophenyl group formed two relatively long-
ranged hydrogen bonds (3.312 Å, 3.327 Å) with K40. Significant
structural changes were observed in and around the activesite
upon binding of C3 which influenced the locations of critical
residues at the active site region. Due to the absence of
intermolecular interactions, the variable region of V36-F41 has
been very flexible and has moved far away from the original
conformation of this loop present in the apoform of enzyme. This
Figure 6. Overlay of the binding modes of the substrate and all the inhibitors at the active site of human chymase enzyme. The Ang
I, C1, C2, and C3 complexes were represented in orange, cyan, violet, and splitpea green colors, respectively.
doi:10.1371/journal.pone.0062740.g006
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movement restrained the phosphinate group of C3 to make any
contacts with the key residues like K40. The binding mode of C3
at the active site has also displayed minimum number of hydrogen
bonds with the active site residues throughout the simulation time
showing its least binding affinity as compared to C1 and C2
(Figure 8B).
Energetics of Chymase-ligand Complexes
The interaction energy which is defined as the sum of the van
der Waals and electrostatic energy contributions to the non-
bonded interaction energies of all the ligands was calculated using
Calculate Interaction Energy protocol implemented in DS. The total
calculated interaction energies were 2141.51, 2106.37, 2110.39,
and 2179.04 for Ang I, C1, C2, and C3 complexes, respectively.
These interaction energy values correlate well with the experi-
mental IC50 values where C1, the most active compound, has
exhibited better interaction energy than other compounds. The
vdw energy of this compound is higher than all other compounds
and it was not compensated by the electrostatic energy. All other
complexes have also demonstrated favorable vdw interaction
energies however these positive vdw interaction energies were
compensated by electrostatic interaction energy in particular for
chymase systems complexed with C3 and substrate. A careful
analysis of the non-bonded interaction energy contribution by
active site residues has revealed that some residues showed
substantial effects over ligand binding (Table 1). The positively
charged K40 residue that interacts with the phosphinate group of
C1 and C2 compounds also exhibited interactions with the 3,4-
difluorophenyl moiety of C3 along with P19 and P29 of substrate,
and has shown major contributions to the electrostatic energy in
the ligand binding. The polar H57 residue has shown positive
electrostatic interaction energies in all the complexes except C1
complex suggesting the importance of this particular residue in
contributing to the biological response. In case of F41, which is
present in the region where the carboxylate group of P29-L10 of
substrate binds in the active site, all the complexes have shown less
contribution from vdw terms, however, their electrostatic energies
have contributed to the interaction energies. The C1 and C2
compounds have shown favorable interaction energies with F191,
G193, and S195 when compared to the C3 ligand. These
interaction energy explorations for the ligands under study have
unveiled the information regarding the extent of participation of
active site residues and ligands impacting the interactions at the
binding cleft of enzyme.
Development of Hybrid Pharmacophore Model
The Receptor-Ligand Pharmacophore Generation protocol of DS
presents the chemical features which instigate key interactions
between the protein and ligand. In this study, the representative
structure obtained from MD simulation trajectories of Chymase-
C1 complex was used as input for structure-based pharmacophore
generation. The Feature Mapping protocol has generated all the
pharmacophoric features present in the bound conformation of
this most active compound at the active site of chymase. The
generated pharmacophore model includes three hydrophobic
(HY), one hydrogen bond donor (HBD) and one negative
ionizable (NI) features. This initial pharmacophore model has
two overlapping HY features on the chlorophenyl ring while the
third HY feature is overlaid on the benzothiophene moiety of the
inhibitor. The HBD and NI features are placed over the amide
and phosphinate groups of the bound inhibitor. In the final
pharmacophore model generated form Chymase-C1 complex, the
overlapping HY feature was removed to simplify the model
(Figure 10A). The representative structure obtained from the MD
simulation of Chymase-Ang I complex was also used as input for
structure-based pharmacophore generation. The initial pharma-
cophore model contained five features including three hydrogen
bond acceptors (HBA), one HBD, and one NI features. Among
these five pharmacophoric features, one HBA and NI features are
most important due to their location in the binding cleft of
enzyme. One of the HBA feature is overlaid on the P19 residue of
Ang I substrate. This feature is oriented towards the positively
charged K40 residue of active site. Both, K40 and F41 residues are
reported to position the substrate at the active site for the effective
catalysis [18]. The presence of negative ionizable (NI) or hydrogen
bond acceptor (HBA) groups instead of PI or HBD groups can
improvethe binding of ligand by forming strong molecular
interactions with the positively charged K40 residue (Figure 10B).
Figure 7. Active site of the substrate (Ang I) complex of the enzyme. (A) Amino acid residues and bound substrate are shown in thin stick
and ball-stick forms, respectively. Residues of substrate are shown in red color and labeled in blue color. Hydrogen bonds are shown in black dashed
lines. (B) The structural changes observed between the active site regions of apoform (grey) and human chymase-substrate complex (orange). The
amino acid residues are shown in thin stick form. Only polar hydrogen atoms are added for clarity.
doi:10.1371/journal.pone.0062740.g007
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The pharmacophore developed from the C1 binding mode also
contains a NI feature close to the K40 residue. Therefore, the
overlapped NI feature of pharmacophore generated from
chymase-C1 complex was deleted. Hence, a final hybrid
pharmacophore model containing one HBD, two HY features
generated from the binding mode of most active compound (C1)
and one NI and one HBA feature generated from Ang I binding
mode was developed (Figure 10C). This pharmacophore model
was generated in order to screen the chemical compounds with NI
and HBA feature as present in Ang I.
Comparison with the Models of Literature
Our hybrid pharmacophore model is in agreement with the
information provided by the former studies. The importance of
hydrophobic features is confirmed for chymase inhibition
[27,30,34]. Moreover, the presence of hydrogen bond acceptor
features is also considered significant for inhibition of chymase
enzyme [35]. In addition, the methodology to develop this hybrid
pharmacophore model development is completely new and
different from the common feature and structure-activity relation-
ship based pharmacophore models employed in our previous
studies for designing human chymase inhibitors [27].
Druglike Database Screening and Molecular Docking
Virtual screening is emerging as a productive and cost-
effective technology in rational drug design for the identification
of novel lead compounds from large virtual database. The final
hybrid pharmacophore model was employed as 3D structural
Figure 8. Intermolecular hydrogen bond plots. Observed intermolecular hydrogen bonds between (A) the substrate (B) inhibitors and active
site residues.
doi:10.1371/journal.pone.0062740.g008
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query in screening drug-like databases including Maybridge, and
Chembrige. From the virtual screening process, 127 and 28
compounds mapping all the five features of the hybrid
pharmacophore model were retrieved from Maybridge and
Chembrige druglike databases, respectively. Finally, a total of
155 compounds satisfying all the filters was selected and
subjected to the molecular docking calculations using GOLD
program along with the three experimentally known chymase
inhibitors.
An initial validation of the docking protocol is performed by
comparing the conformation, position, and orientation (the pose)
of a ligand as obtained from docking with the one determined
experimentally with X-ray crystallography. Correctly redocking
the crystallographically observed inhibitor is a minimum require-
Figure 9. Binding modes and molecular interactions of the three inhibitors. (A) Overlay of the binding modes of all the inhibitors at the
active site of human chymase enzyme. (B) C1 in cyan (C) C2 in violet (D) C3 in splitpea green colors at the active site of enzyme. The hydrogen bond
and p-interactions were displayed in black dashed and brown solid lines, respectively. Amino acid residues and inhibitors are shown in stick and ball-
stick forms whereas the gray, cyan, violet, and splitpea green cartoons represent apoform of enzyme, C13, C14, and C15 complexes, respectively. Only
polar hydrogen atoms are added for clarity.
doi:10.1371/journal.pone.0062740.g009
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ment to determine whether the program is applicable to this
system or not. Crystal structure with the PDB code 3N7O bound
with an inhibitor molecule (N7O) was selected as receptor and the
active site was defined with a 10 Å radius around the ligand
present in the crystal structure. The top conformation of ligand
predicted by GOLD program was very close to the crystal
structure-bound conformation. The RMSD between the docked
pose and its bound conformation in the crystal structure is 0.53 Å
indicating that GOLD is able to reproduce correct pose
(Figure 11).
In order to find out whether there were interactions between the
key residues of the active site of enzyme and the docked
compounds, the docking experiment served as a snapshot of
molecular interactions The binding modes of all the docked
compounds were analyzed for their molecular interactions at the
active site. The most active compound C1 in the training set has
scored the GOLD fitness score of 67.944. While, among 155 hit
compounds, 21 hits demonstrated higher GOLD fitness scores
thanC1, and were selected for further study.
The binding modes of the possible inhibitors for human
chymase were further analyzed using Autodock 4.2. This program
takes more time but predicts the binding conformations more
accurately and results in the binding energy of each docked
compound. As an efficient post-docking filtering protocol, the
electronic parameters such as highest occupied molecular orbital
(HOMO), least unoccupied molecular orbital (LUMO), and
energy gap(DE) values along with the binding free energies were
also calculated for all the compounds. Finally, four compounds
were listed as possible chymase inhibitors on the basis of strong
binding interaction at active site of target protein, good GOLD
Fitness score, and favorable Autodock binding free energy along
with highly reactive electronic properties, (Figure 12). The GOLD
fitness score and the calculated binding energy values along with
the electronic parameters for all the final hitsare given in Table 2.
The binding modes and molecularinteractions between the final
hits and theactive site components of the enzyme are discussedbe-
low.
Binding Mode of Hit 1
The binding mode of Hit 1 within the active site of chymase
has been analyzed. This compound was identified from
Maybridge database. The GOLD Fitness score and Autodock
binding free energy values for Hit 1 were 72.018 and
26.42 kcal/mol, respectively. This hit compound has shown a
different binding mode compared to that of C1, the most active
compound, but bounds very tightly with the catalytic compo-
nents. As shown in the molecular docking result, the suitable
shape of this hit compound helped it to bind tightly with the
binding pocket of chymase, facilitating p…cationic interactions
between K40 and aromatic ring of Hit 1(Figure 13A).
Moreover, a network of hydrogen bonds between Hit 1 and
key amino acids including K192(2.971 Å), G193(2.674 Å), S195
(3.031 Å), Y215(2.825 Å), and R217(3.047 Å) of binding site
cleft was also formed, which suggested that Hit 1could be a
potent inhibitor of human chymase.
Binding Mode of Hit 2
Hit 2 had a GOLD Fitness score of 70.268 and an Autodock
binding free energy of –5.72 kcal/mol. The binding mode of Hit 2
is similar to Hit 1. Upon the examination of docking features
between Hit 2 and chymase it was found that various kinds of close
contacts which include p…cationic, p…s, hydrophobic and
hydrogen bonding were formed between the hit compound and
active site region of enzyme. The p…cationic interaction was
observed between positively charged residue K40 and aromatic
ring of Hit 2 as depicted in Figure 13B. A p…s interaction was
also found between the hydrophobic residue F191 and benzodiox-
epine ring of Hit 2. Furthermore, a number of hydrogen bonds
were formed between K192, G193, S195, and R217 of active site
and Hit 2compound.
Binding Mode of Hit 3
The binding conformation of Hit 3 within the active site of
chymase had a GOLD Fitness score of 70.107 and an Autodock
binding free energy of 26.21 kcal/mol. It also bonded to the
active site in a similar fashion to the other two hit compounds. Hit
3 formed a number of hydrogen bonds with the catalytically
important residues like K40(2.019, 2.011, and 3.0 Å), K192(2.616
Å), G193(3.124 Å), S195(3.110 Å), and R217(3.124 Å). It was also
able to establish hydrophobic interaction with F191 of binding site
cleft. Due to its tight binding to active site of enzyme, and presence
of key interactions, Hit 3 could be a potent inhibitor of chymase
enzyme.
Table 1. Calculated non-bonded interaction energies between the inhibitors and important active site residues.
Residue AngI C1 C2 C3
vdw Elec vdw Elec vdw Elec vdw Elec
K40 21.18 2110.52 2.12 2110.45 21.95 2101.44 22.215 294.74
F41 21.25 5.11 20.61 7.88 20.48 5.14 20.17 11.31
H57 21.55 5.54 24.91 20.13 23.28 6.20 21.65 3.86
D102 20.07 229.07 20.24 30.67 20.38 39.82 20.40 40.97
F191 20.74 27.44 23.09 0.73 21.58 2.18 22.40 214.72
K192 1.56 244.52 24.82 237.34 25.14 253.05 22.12 252.93
G193 20.57 2.28 1.60 211.74 0.01 27.41 20.15 22.40
S195 20.30 2.55 20.52 7.26 22.01 8.21 2.63 22.08
Y215 24.64 8.15 4.87 24.32 21.33 210.9 21.80 21.61
R217 21.27 25.80 22.57 20.17 20.59 20.032 20.04 21.09
doi:10.1371/journal.pone.0062740.t001
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Binding Mode of Hit 4
The binding mode of this hit compound is similar to C2 and C3
compounds studied in this research exertion. The molecular
interactions exhibited by this hit compound included the hydrogen
bond interactions with K40 (2.628 Å), H57 (2.933 Å), G193(2.680
Å), (3.183 Å), and S195(3.294Å) (Figure 13D). The GOLD Fitness
score and Autodock binding free energy values for Hit 4 were
68.195 and 25.11 kcal/mol, respectively. The lower energy gap
value was also promising for this compound which further
enhanced its constancy to be apotential lead compound.
A search using SciFinder Scholar and PubChem Structure
search tools has also confirmed that the identified hits were not
reported elsewhere earlier for the inhibition of human chymase.
Conclusions
Chymase is an enzyme of the hydrolase class that catalyzes
the hydrolysis of peptide bonds and it is the major extravascular
source of vasoactive Ang II, which is generated with exceptional
efficiency by human chymase via hydrolysis of the Phe-8–His-9
bond of Ang I. The inhibition of chymase is likely to divulge
therapeutic ways for the treatment of cardiovascular diseases,
allergic inflammation, and fibrotic disorders. Therefore, several
Figure 10. Development of hybrid pharmacophore model. The key pharmacophoric features generated from the binding modes of (A) C1
and (B) Ang I. The amino acid residues of the enzyme are shown in gray thin stick form whereas the bound C1 and Ang I are shown in thick stick form.
The secondary structure cartoon of the enzyme is colored based on the hydrophobicity of the amino acid residues. (C) Final hybrid pharmacophore
model (D) Hybrid pharmacophore model with distance constraints.
doi:10.1371/journal.pone.0062740.g010
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peptide and non-peptide inhibitors of chymase have been
synthesized by various research groups. We selected three
experimentally known chymase inhibitors which have very
similar chemical structures but exhibited the considerable
differences in terms of chymase inhibitory activity with the
aim of finding the reasons for the difference observed in their
inhibitory profiles caused by the subtle structural variation. The
disparities in hydrogen bond networks and non-bonded inter-
action energies between the inhibitor and catalytic residues
along with binding conformations of the inhibitors have
explained the difference in their biological activities very
convincingly. The evaluation of hydrogen bond network has
demonstrated that the most active compound has formed the
maximum number of short-ranged hydrogen bond interactions
with the positively charged K40 residue at the active site. This
residue was reported to hold an important role in the substrate
recognition and hydrolysis process. Thus, formation of strong
interactions with important catalytic K40 residue by an
inhibitor is considered very significant for effective inhibitor
binding. The key structural changes comprise of the secondary
structural changes spotted at the regions of V36-F41, and
G216-A220 residues that determine the conformation and
flexibility of very important catalytic K40, and R217 residues.
Interestingly, the region around K40 has exhibited less flexibility
in substrate as well asmost active C1 and less active C2
complexes whereas this region has shown maximum flexibility
in the least active C3 complex. In the G216-A220 region, all of
these five residues were present in variable regions thus forming
a helix in the least active C3 complex. However, this loop
region showed more rigidity in the case of substrate and less
active C2 complexes while two residues of G216-A220 region
were in variable regions in C1complex. These appreciable
distinctions in binding modes, structural differences, and key
interactions determined the basis for the potent inhibitory
profile of C1, slightly reduced activity of C2, and the least
active nature of C3. The dynamic structures of chymase-C1 and
chymase-Ang I complexes were employed in the development of
a hybrid pharmacophore model which was subjected to
screening of the druglike databases to select the compounds
containing all the hybrid pharmacophoric features identified
from both the most active inhibitor and substrate. The
compounds that resulted from the pharmacophore filtering
were docked into the active site of human chymase and the hits
those bind well at the active site, exhibited key interactions and
Figure 11. Overlay of the docked pose (green) of inhibitor with its crystal structure conformation (gray).
doi:10.1371/journal.pone.0062740.g011
Table 2. Results of molecular docking using GOLD and
Autodock programs along with electronic parameters














C1 C1 67.944 26.74 20.100 20.082 0.018
C2 C2 62.581 25.51 20.206 20.144 0.062
C3 C3 51.236 25.07 20.117 20.083 0.034
Hit 1 JFD_01598 72.018 26.42 20.189 20.093 0.096
Hit 2 SCR_00479 70.268 25.72 20.254 20.184 0.070
Hit 3 RJC_02222 70.107 26.21 20.135 20.127 0.008
Hit 4 HTS_02685 68.195 25.11 20.279 20.250 0.029
doi:10.1371/journal.pone.0062740.t002
Figure 12. The 2D chemical structures of the final identified hit
compounds.
doi:10.1371/journal.pone.0062740.g012
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favorable electronic properties were identified as possible
inhibitors for chymase enzyme. Finally four compounds of
diverse chemical scaffolds were selected as potential leads to be
used in novel and potent chymase inhibitor design. This study
not only explains the inhibitory mechanism of the inhibitors but
also provides important structural insights which broads our
knowledge for drug designing against enzyme targets.
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Figure 13. Molecular docking results. The binding modes of (A) Hit 1 (B) Hit 2 (C) Hit 3 and (D) Hit 4 at the active site of the enzyme. The amino
acid residues and bound ligands are shown in stick representations. The hydrogen bond, and p-interactions are shown in black dashed, and brown
solid lines. Only polar hydrogen atoms are added for clarity.
doi:10.1371/journal.pone.0062740.g013
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